GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immuron Ltd (FRA:ANW) » Definitions » Debt-to-Revenue

Immuron (FRA:ANW) Debt-to-Revenue : 0.00 (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Immuron Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Immuron's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.00 Mil. Immuron's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.00 Mil. Immuron's annualized Revenue for the quarter that ended in Dec. 2023 was €2.89 Mil. Immuron's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.00.


Immuron Debt-to-Revenue Historical Data

The historical data trend for Immuron's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immuron Debt-to-Revenue Chart

Immuron Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only - 0.03 0.14 0.27 0.11

Immuron Semi-Annual Data
Jun15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.49 0.20 0.17 0.08 -

Competitive Comparison of Immuron's Debt-to-Revenue

For the Biotechnology subindustry, Immuron's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immuron's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immuron's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Immuron's Debt-to-Revenue falls into.



Immuron Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Immuron's Debt-to-Revenue for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.024 + 0.093) / 1.118
=0.10

Immuron's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2023) Revenue data.


Immuron Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Immuron's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Immuron (FRA:ANW) Business Description

Traded in Other Exchanges
Address
Chapman Street, Unit 10, 25-37, Blackburn North, Melbourne, VIC, AUS, 3130
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.

Immuron (FRA:ANW) Headlines

No Headlines